Heng Lu

Dr. Heng Lu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
YZYiqi Zhang
Yiqi Zhang
AZAng Zheng
Ang Zheng
YSYue Shi
Yue Shi
HLHeng Lu
Heng Lu
Small nucleolar RNAs (snoRNAs) have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. Samples from The Cancer Genome Atlas (TCGA) were reviewed. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue samples. SNORA5A was significantly down-regulated in breast cancer, and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced a high concentration of tumor-associated macrophages M1 and a low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relationship with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.

8 June 2026 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
YZYiqi Zhang
Yiqi Zhang
ZGZiyu Gao
Ziyu Gao
XMXiaohu Ma
Xiaohu Ma
YLYinlin Li
Yinlin Li
WSWeiming Sun
Weiming Sun
HLHeng Lu
Heng Lu

29 October 2025 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
YZYiqi Zhang
Yiqi Zhang
ZJZining Jin
Zining Jin
YWYi Wu
Yi Wu
XTXueying Tang
Xueying Tang
CWChunyu Wang
Chunyu Wang
AZAng Zheng
Ang Zheng
Triple-negative breast cancer (TNBC) is considered a highly heterogeneous disease. Androgen receptor (AR)-positive TNBC is a subtype with distinct molecular features. However, the molecular mechanism underlying the modulation of the AR signaling pathway in TNBC is still elusive. BPTF-associated protein of 18 kDa (BAP18) was significantly upregulated in AR-positive TNBC samples and was positively correlated with advanced disease stage and poor prognosis. BAP18 was shown to act as a transcriptional corepressor of AR in AR-positive TNBC cells and is involved in the promotion of AR-positive TNBC. Mechanically, BAP18 associates with AR and the SIN3A/HDAC subcomplex. BAP18 facilitates the recruitment of SIN3A/HDAC to androgen response elements (AREs) in the promoter regions of P21 and PTEN, subsequently leading to a reduced level of histone H4 acetylation on AREs. Our study revealed that BAP18, which acts as a novel AR corepressor, is involved in AR-positive TNBC progression, suggesting that BAP18 could be a potential therapeutic target for AR-positive TNBC patients.

29 November 2022 in Research Square
Verified
Preprint
Open access
PDF file
YZYiqi Zhang
Yiqi Zhang
AZAng Zheng
Ang Zheng
YSYue Shi
Yue Shi
HLHeng Lu
Heng Lu
SnoRNAs have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. This study reviewed samples from TCGA. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue sample. SNORA5A was significantly down-regulated in breast cancer and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced high concentration of tumor-associated macrophages M1 and low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relation with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. Hence, SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.